4-(2-methoxyethyl)-1H-pyrazole | 1696383-18-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(2-methoxyethyl)-1H-pyrazole
• CAS: 1696383-18-2
• 化学式: C₆H₁₀N₂O
• 分子量: 126.158
• InChiKey: GXMNNSYJOLBLGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloro-N-(2,4-dimethoxybenzyl)-5-nitrobenzenesulfonamide 、 4-(2-methoxyethyl)-1H-pyrazole 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 N-(2,4-dimethoxybenzyl)-2-[4-(2-methoxyethyl)-1H-pyrazol-1-yl]-5-nitrobenzenesulfonamide
  参考文献：
  名称：

  [EN] AROMATIC SULFONAMIDE DERIVATIVES
  [FR] DÉRIVÉS SULFONAMIDES AROMATIQUES

  摘要：

  公开号：

  WO2017191000A9

文献信息

• New compounds, pharmaceutical compositions and uses thereof
  申请人：ROTH Gerald Juergen

  公开号：US20120214782A1

  公开（公告）日：2012-08-23

  The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  这项发明涉及公式I的新化合物，以及它们作为药物的用途，它们的治疗用途的方法，以及含有它们的药物组合物。
• 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS
  申请人：Fiegen Dennis

  公开号：US20110263549A1

  公开（公告）日：2011-10-27

  The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, R 1 can represent a group A selected from among the group comprising —O—R 3 , —NR 3 R 4 , —CR 3 R 4 R 5 , -(ethyne)-R 3 , —S—R 3 , —SO—R 3 , and SO 2 —R 3 , or R 1 represents a group B selected from among the group comprising: —C 6-10 -aryl;—a five-membered to ten-membered, monocyclic or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heteroaryl is linked to the structure according to formula 1 via a C atom or an N atom;—a three-membered to ten-membered, monocyclic or bicyclic, saturated or partially saturated heterocycle containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heterocycle is linked to the structure according to formula 1 via a C atom or an N atom; and—a 5-membered to 11-membered spiro group which can optionally contain 1, 2, or 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said spiro group is linked to the structure according to formula 1 via a C atom or an N atom, wherein said group B can be optionally substituted as described in claims 1, and R 3 ,R 4 ,R 5 ,R 6 , and m can have the meanings indicated in claim 1. The invention also relates to pharmaceutical compositions containing said compounds.

  该发明涉及具有以下式的新型取代萘啉类化合物，以及其药理学上可接受的盐、对映体异构体、对映体、消旋体、水合物或溶剂合物。在式中，R1可以表示从包括—O—R3、—NR3R4、—CR3R4R5、-(乙炔)-R3、—S—R3、—SO—R3和SO2—R3的群组中选择的A基团，或者R1表示从包括：—C6-10-芳基；—含有1至3个异原子（从N、O和S中独立选择）的五元至十元的单环或双环杂环芳基，其中所述杂环芳基通过碳原子或氮原子与式1中的结构连接；—含有1至3个异原子（从N、O和S中独立选择）的三元至十元的单环或双环、饱和或部分饱和的杂环，其中所述杂环通过碳原子或氮原子与式1中的结构连接；和—一个含有1、2或3个异原子（从N、O和S中独立选择）的五元至十一元的螺环，其中所述螺环通过碳原子或氮原子与式1中的结构连接，其中所述基团B可以按照权利要求中描述的方式被取代，R3、R4、R5、R6和m可以具有权利要求中所示的含义。该发明还涉及含有所述化合物的药物组合物。
• [EN] BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF<br/>[FR] COMPOSÉS PONTÉS EN TANT QU'INHIBITEUR ET DÉGRADEUR DE KRAS G12D ET LEUR UTILISATION
  申请人：BEIGENE LTD

  公开号：WO2022148422A1

  公开（公告）日：2022-07-14

  Provided herein are Bridged Compounds having the following structures: (I) wherein R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, R3c, R3d, R4, R5, R6, R7, R8, m1, m2, m3, n2, n3, n4, q, X1, X2, Y1, Y2, L1and ring A are as defined herein, compositions comprising an effective amount of a Bridged Compound, and methods for treating or preventing various diseases, e.g., pancreatic cancer, or a condition treatable or preventable by inhibition of the function of KRAS protein. In another aspect, a Bridged Compound is useful for treating or preventing a condition treatable or preventable by inhibition of the function of KRAS protein with G12D mutation. In another aspect, a Bridged Compound is useful for treating or preventing a condition treatable or preventable by inhibition of a RAS/MAPK pathway.

  本文提供了具有以下结构的桥接化合物：（I），其中R1a，R1b，R1c，R1d，R2a，R2b，R2c，R2d，R3a，R3b，R3c，R3d，R4，R5，R6，R7，R8，m1，m2，m3，n2，n3，n4，q，X1，X2，Y1，Y2，L1和环A的定义如本文所述，包含有效量的桥接化合物的组合物，以及用于治疗或预防各种疾病的方法，例如胰腺癌或可通过抑制KRAS蛋白功能来治疗或预防的疾病。在另一个方面，桥接化合物可用于治疗或预防可通过抑制具有G12D突变的KRAS蛋白功能来治疗或预防的疾病。在另一个方面，桥接化合物可用于治疗或预防可通过抑制RAS / MAPK途径来治疗或预防的疾病。
• Aromatic sulfonamide derivatives
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US10844016B2

  公开（公告）日：2020-11-24

  Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

  式（I）的取代芳香族磺酰胺类药物组合物和包含所述化合物的组合物，以及使用所述化合物制造治疗或预防疾病的药物组合物。
• AROMATIC SULFONAMIDE DERIVATIVES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3458443B1

  公开（公告）日：2020-08-19